New drug shows promise in tough lung cancer fight
NCT ID NCT07016230
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests a drug called tarlatamab in people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. About 40 adults will receive the drug intravenously to see if it shrinks tumors and how long that effect lasts. Researchers will also collect blood and tumor samples to understand why some patients respond and others do not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC/LOCALLY ADVANCED SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
RECRUITINGVillejuif, France
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.